ARTICLE | Clinical News

GTx gains on Phase II breast cancer milestone

September 8, 2016 7:00 AM UTC

GTx Inc. (NASDAQ:GTXI) added $0.14 (22%) to $0.77 on Thursday after it said a sufficient clinical benefit had been shown for the low-dose cohort of a Phase II trial of breast cancer candidate enobosarm ( GTx-024) to proceed to its second and final stage.

For each of the trial's two cohorts to advance, a benefit has to be shown in at least three of 18 evaluable patients after 24 weeks. The study is evaluating 9 mg and 18 mg daily doses of enobosarm to treat estrogen receptor-positive, androgen receptor-positive breast cancer. Each cohort's enrollment would grow to 44 patients in the trial's second stage. ...